Short lookback periods causing exaggerated stroke risk estimates in atrial fibrillation may expose patients to unnecessary anticoagulant treatment
Purpose The purpose was to investigate how different lookback periods in observational registry studies affect estimates of stroke risk in patients with atrial fibrillation and stroke risk score CHA2DS2‐VASc 1, a level where the appreciated risk is likely to affect decisions about oral anticoagulati...
Gespeichert in:
Veröffentlicht in: | Pharmacoepidemiology and drug safety 2019-08, Vol.28 (8), p.1054-1059 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1059 |
---|---|
container_issue | 8 |
container_start_page | 1054 |
container_title | Pharmacoepidemiology and drug safety |
container_volume | 28 |
creator | Friberg, Leif |
description | Purpose
The purpose was to investigate how different lookback periods in observational registry studies affect estimates of stroke risk in patients with atrial fibrillation and stroke risk score CHA2DS2‐VASc 1, a level where the appreciated risk is likely to affect decisions about oral anticoagulation.
Methods
All 354 854 individuals in Sweden with a hospital diagnosis of atrial fibrillation during 2010‐2016 were included. At least 13 years of observational data prior to inclusion was available for all patients. The prevalence of hypertension, heart failure, diabetes, previous thromboembolism, and vascular disease was estimated from data with different lookback periods. The incident stroke rates at CHA2DS2‐VASc score 1 was then assessed using data with successively longer lookback periods.
Results
Depending on duration of lookback period, the proportion of patients with heart failure varied 2.7 times, thromboembolism 3.7 times, hypertension 4.0 times, and diabetes and vascular disease both approximately 4.5 times. During follow‐up, 22 237 patients suffered an ischaemic stroke. The estimated risk without anticoagulant treatment at CHA2DS2‐VASc score 1 was 51% higher if the scores had been calculated with the shortest lookback period than if all information had been used.
Conclusions
Short lookback periods underestimate comorbidity, cause high‐risk patients to be misclassified as low risk, and overestimate stroke risk at CHA2DS2‐VASc 1. This may lead to unnecessary anticoagulant treatment of true low‐risk patients. Transparency regarding lookback periods is essential for interpretation and comparison of registry studies. |
doi_str_mv | 10.1002/pds.4793 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2232067409</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2267682530</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3493-5fab06b114f9349686ff86ae4df7269473302d3ea260d5d580684ce4b7fc8cac3</originalsourceid><addsrcrecordid>eNp1kc2KFTEQhYMozjgKPoEE3LjpMX-d7ixlxj8YUBhdN-l05Zq53UmbSqP3NXxic51RQXBVxclXh6ocQp5yds4ZEy_XCc9VZ-Q9csqZMQ1v2-7-sW9l07fanJBHiDeM1TejHpITyTkXUvNT8uP6S8qFzintR-v2dIUc0oTU2Q1D3FH4bnc7yLbARLHktAeaA-4pYAlLVZGGSG3Jwc7UhzGHebYlpEgXe6jDa0Kga1UgFqQl0S1GcIBo84HaWIJLdrfNtaMlgy1L5R6TB97OCE_u6hn5_Ob1p4t3zdWHt-8vXl01Tiojm9bbkemRc-VNFXSvve-1BTX5TmijOimZmCRYodnUTm3PdK8cqLHzrnfWyTPy4tZ3zenrVg8aloAO6gER0oaDEFIw3SlmKvr8H_QmbTnW7SqlO92LVrK_hi4nxAx-WHP9pHwYOBuOOQ01p-GYU0Wf3Rlu4wLTH_B3MBVoboFvYYbDf42Gj5fXvwx_ApIEn6E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2267682530</pqid></control><display><type>article</type><title>Short lookback periods causing exaggerated stroke risk estimates in atrial fibrillation may expose patients to unnecessary anticoagulant treatment</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Friberg, Leif</creator><creatorcontrib>Friberg, Leif</creatorcontrib><description>Purpose
The purpose was to investigate how different lookback periods in observational registry studies affect estimates of stroke risk in patients with atrial fibrillation and stroke risk score CHA2DS2‐VASc 1, a level where the appreciated risk is likely to affect decisions about oral anticoagulation.
Methods
All 354 854 individuals in Sweden with a hospital diagnosis of atrial fibrillation during 2010‐2016 were included. At least 13 years of observational data prior to inclusion was available for all patients. The prevalence of hypertension, heart failure, diabetes, previous thromboembolism, and vascular disease was estimated from data with different lookback periods. The incident stroke rates at CHA2DS2‐VASc score 1 was then assessed using data with successively longer lookback periods.
Results
Depending on duration of lookback period, the proportion of patients with heart failure varied 2.7 times, thromboembolism 3.7 times, hypertension 4.0 times, and diabetes and vascular disease both approximately 4.5 times. During follow‐up, 22 237 patients suffered an ischaemic stroke. The estimated risk without anticoagulant treatment at CHA2DS2‐VASc score 1 was 51% higher if the scores had been calculated with the shortest lookback period than if all information had been used.
Conclusions
Short lookback periods underestimate comorbidity, cause high‐risk patients to be misclassified as low risk, and overestimate stroke risk at CHA2DS2‐VASc 1. This may lead to unnecessary anticoagulant treatment of true low‐risk patients. Transparency regarding lookback periods is essential for interpretation and comparison of registry studies.</description><identifier>ISSN: 1053-8569</identifier><identifier>EISSN: 1099-1557</identifier><identifier>DOI: 10.1002/pds.4793</identifier><identifier>PMID: 31112361</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Aged ; Anticoagulants ; Anticoagulants - administration & dosage ; atrial fibrillation ; Atrial Fibrillation - complications ; Atrial Fibrillation - drug therapy ; Brain Ischemia - epidemiology ; Brain Ischemia - etiology ; Brain Ischemia - prevention & control ; Cardiac arrhythmia ; CHA2DS2‐VASc ; Congestive heart failure ; Diabetes ; Diabetes mellitus ; epidemiology ; Female ; Fibrillation ; Follow-Up Studies ; Health risks ; Heart failure ; Humans ; Hypertension ; Male ; Patients ; pharmacoepidemiology ; Registries ; Risk Factors ; risk stratification ; Stroke ; Stroke - epidemiology ; Stroke - etiology ; Stroke - prevention & control ; Sweden ; Thromboembolism ; Time Factors ; Unnecessary Procedures ; Vascular diseases</subject><ispartof>Pharmacoepidemiology and drug safety, 2019-08, Vol.28 (8), p.1054-1059</ispartof><rights>2019 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3493-5fab06b114f9349686ff86ae4df7269473302d3ea260d5d580684ce4b7fc8cac3</citedby><cites>FETCH-LOGICAL-c3493-5fab06b114f9349686ff86ae4df7269473302d3ea260d5d580684ce4b7fc8cac3</cites><orcidid>0000-0002-7453-0157</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpds.4793$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpds.4793$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31112361$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Friberg, Leif</creatorcontrib><title>Short lookback periods causing exaggerated stroke risk estimates in atrial fibrillation may expose patients to unnecessary anticoagulant treatment</title><title>Pharmacoepidemiology and drug safety</title><addtitle>Pharmacoepidemiol Drug Saf</addtitle><description>Purpose
The purpose was to investigate how different lookback periods in observational registry studies affect estimates of stroke risk in patients with atrial fibrillation and stroke risk score CHA2DS2‐VASc 1, a level where the appreciated risk is likely to affect decisions about oral anticoagulation.
Methods
All 354 854 individuals in Sweden with a hospital diagnosis of atrial fibrillation during 2010‐2016 were included. At least 13 years of observational data prior to inclusion was available for all patients. The prevalence of hypertension, heart failure, diabetes, previous thromboembolism, and vascular disease was estimated from data with different lookback periods. The incident stroke rates at CHA2DS2‐VASc score 1 was then assessed using data with successively longer lookback periods.
Results
Depending on duration of lookback period, the proportion of patients with heart failure varied 2.7 times, thromboembolism 3.7 times, hypertension 4.0 times, and diabetes and vascular disease both approximately 4.5 times. During follow‐up, 22 237 patients suffered an ischaemic stroke. The estimated risk without anticoagulant treatment at CHA2DS2‐VASc score 1 was 51% higher if the scores had been calculated with the shortest lookback period than if all information had been used.
Conclusions
Short lookback periods underestimate comorbidity, cause high‐risk patients to be misclassified as low risk, and overestimate stroke risk at CHA2DS2‐VASc 1. This may lead to unnecessary anticoagulant treatment of true low‐risk patients. Transparency regarding lookback periods is essential for interpretation and comparison of registry studies.</description><subject>Aged</subject><subject>Anticoagulants</subject><subject>Anticoagulants - administration & dosage</subject><subject>atrial fibrillation</subject><subject>Atrial Fibrillation - complications</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Brain Ischemia - epidemiology</subject><subject>Brain Ischemia - etiology</subject><subject>Brain Ischemia - prevention & control</subject><subject>Cardiac arrhythmia</subject><subject>CHA2DS2‐VASc</subject><subject>Congestive heart failure</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>epidemiology</subject><subject>Female</subject><subject>Fibrillation</subject><subject>Follow-Up Studies</subject><subject>Health risks</subject><subject>Heart failure</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Male</subject><subject>Patients</subject><subject>pharmacoepidemiology</subject><subject>Registries</subject><subject>Risk Factors</subject><subject>risk stratification</subject><subject>Stroke</subject><subject>Stroke - epidemiology</subject><subject>Stroke - etiology</subject><subject>Stroke - prevention & control</subject><subject>Sweden</subject><subject>Thromboembolism</subject><subject>Time Factors</subject><subject>Unnecessary Procedures</subject><subject>Vascular diseases</subject><issn>1053-8569</issn><issn>1099-1557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc2KFTEQhYMozjgKPoEE3LjpMX-d7ixlxj8YUBhdN-l05Zq53UmbSqP3NXxic51RQXBVxclXh6ocQp5yds4ZEy_XCc9VZ-Q9csqZMQ1v2-7-sW9l07fanJBHiDeM1TejHpITyTkXUvNT8uP6S8qFzintR-v2dIUc0oTU2Q1D3FH4bnc7yLbARLHktAeaA-4pYAlLVZGGSG3Jwc7UhzGHebYlpEgXe6jDa0Kga1UgFqQl0S1GcIBo84HaWIJLdrfNtaMlgy1L5R6TB97OCE_u6hn5_Ob1p4t3zdWHt-8vXl01Tiojm9bbkemRc-VNFXSvve-1BTX5TmijOimZmCRYodnUTm3PdK8cqLHzrnfWyTPy4tZ3zenrVg8aloAO6gER0oaDEFIw3SlmKvr8H_QmbTnW7SqlO92LVrK_hi4nxAx-WHP9pHwYOBuOOQ01p-GYU0Wf3Rlu4wLTH_B3MBVoboFvYYbDf42Gj5fXvwx_ApIEn6E</recordid><startdate>201908</startdate><enddate>201908</enddate><creator>Friberg, Leif</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7453-0157</orcidid></search><sort><creationdate>201908</creationdate><title>Short lookback periods causing exaggerated stroke risk estimates in atrial fibrillation may expose patients to unnecessary anticoagulant treatment</title><author>Friberg, Leif</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3493-5fab06b114f9349686ff86ae4df7269473302d3ea260d5d580684ce4b7fc8cac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Anticoagulants</topic><topic>Anticoagulants - administration & dosage</topic><topic>atrial fibrillation</topic><topic>Atrial Fibrillation - complications</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Brain Ischemia - epidemiology</topic><topic>Brain Ischemia - etiology</topic><topic>Brain Ischemia - prevention & control</topic><topic>Cardiac arrhythmia</topic><topic>CHA2DS2‐VASc</topic><topic>Congestive heart failure</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>epidemiology</topic><topic>Female</topic><topic>Fibrillation</topic><topic>Follow-Up Studies</topic><topic>Health risks</topic><topic>Heart failure</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Male</topic><topic>Patients</topic><topic>pharmacoepidemiology</topic><topic>Registries</topic><topic>Risk Factors</topic><topic>risk stratification</topic><topic>Stroke</topic><topic>Stroke - epidemiology</topic><topic>Stroke - etiology</topic><topic>Stroke - prevention & control</topic><topic>Sweden</topic><topic>Thromboembolism</topic><topic>Time Factors</topic><topic>Unnecessary Procedures</topic><topic>Vascular diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Friberg, Leif</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacoepidemiology and drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Friberg, Leif</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Short lookback periods causing exaggerated stroke risk estimates in atrial fibrillation may expose patients to unnecessary anticoagulant treatment</atitle><jtitle>Pharmacoepidemiology and drug safety</jtitle><addtitle>Pharmacoepidemiol Drug Saf</addtitle><date>2019-08</date><risdate>2019</risdate><volume>28</volume><issue>8</issue><spage>1054</spage><epage>1059</epage><pages>1054-1059</pages><issn>1053-8569</issn><eissn>1099-1557</eissn><abstract>Purpose
The purpose was to investigate how different lookback periods in observational registry studies affect estimates of stroke risk in patients with atrial fibrillation and stroke risk score CHA2DS2‐VASc 1, a level where the appreciated risk is likely to affect decisions about oral anticoagulation.
Methods
All 354 854 individuals in Sweden with a hospital diagnosis of atrial fibrillation during 2010‐2016 were included. At least 13 years of observational data prior to inclusion was available for all patients. The prevalence of hypertension, heart failure, diabetes, previous thromboembolism, and vascular disease was estimated from data with different lookback periods. The incident stroke rates at CHA2DS2‐VASc score 1 was then assessed using data with successively longer lookback periods.
Results
Depending on duration of lookback period, the proportion of patients with heart failure varied 2.7 times, thromboembolism 3.7 times, hypertension 4.0 times, and diabetes and vascular disease both approximately 4.5 times. During follow‐up, 22 237 patients suffered an ischaemic stroke. The estimated risk without anticoagulant treatment at CHA2DS2‐VASc score 1 was 51% higher if the scores had been calculated with the shortest lookback period than if all information had been used.
Conclusions
Short lookback periods underestimate comorbidity, cause high‐risk patients to be misclassified as low risk, and overestimate stroke risk at CHA2DS2‐VASc 1. This may lead to unnecessary anticoagulant treatment of true low‐risk patients. Transparency regarding lookback periods is essential for interpretation and comparison of registry studies.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31112361</pmid><doi>10.1002/pds.4793</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-7453-0157</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1053-8569 |
ispartof | Pharmacoepidemiology and drug safety, 2019-08, Vol.28 (8), p.1054-1059 |
issn | 1053-8569 1099-1557 |
language | eng |
recordid | cdi_proquest_miscellaneous_2232067409 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Aged Anticoagulants Anticoagulants - administration & dosage atrial fibrillation Atrial Fibrillation - complications Atrial Fibrillation - drug therapy Brain Ischemia - epidemiology Brain Ischemia - etiology Brain Ischemia - prevention & control Cardiac arrhythmia CHA2DS2‐VASc Congestive heart failure Diabetes Diabetes mellitus epidemiology Female Fibrillation Follow-Up Studies Health risks Heart failure Humans Hypertension Male Patients pharmacoepidemiology Registries Risk Factors risk stratification Stroke Stroke - epidemiology Stroke - etiology Stroke - prevention & control Sweden Thromboembolism Time Factors Unnecessary Procedures Vascular diseases |
title | Short lookback periods causing exaggerated stroke risk estimates in atrial fibrillation may expose patients to unnecessary anticoagulant treatment |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T14%3A55%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Short%20lookback%20periods%20causing%20exaggerated%20stroke%20risk%20estimates%20in%20atrial%20fibrillation%20may%20expose%20patients%20to%20unnecessary%20anticoagulant%20treatment&rft.jtitle=Pharmacoepidemiology%20and%20drug%20safety&rft.au=Friberg,%20Leif&rft.date=2019-08&rft.volume=28&rft.issue=8&rft.spage=1054&rft.epage=1059&rft.pages=1054-1059&rft.issn=1053-8569&rft.eissn=1099-1557&rft_id=info:doi/10.1002/pds.4793&rft_dat=%3Cproquest_cross%3E2267682530%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2267682530&rft_id=info:pmid/31112361&rfr_iscdi=true |